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Abstract  
Introduction: The use of antiretroviral therapy (ART) has become a standard of care for the treatment of HIV infection. However, cost and 
resistance to ART are major obstacles for access to treatment especially in resource-limited settings. In this study, we aimed to assess the 
magnitude and associated factors of Immunological failure among adult and adolescent HIV infected Patients (with age '15yrs) on Highly Active 
Antiretroviral Therapy (HAART) in St. Luke and Tulu Bolo Hospitals, Oromia Region, Ethiopia. Methods: A retrospective follow-up study was 
conducted among HIV-infected patients initiated 1st line ART at St. Luke and Tulu Bolo Hospitals, South West Shoa Zone, Oromia, Ethiopia. 
Results: A total of 828 patient charts were reviewed. 477(57.6%) were female and the median age was 32 years. The median baseline CD4 count 
was 148cells/mm3. The most common prescribed ART was TDF based (36.7%). Out of 828 patients chart reviewed 6.8% (56) were developed 
immunological failure. Out of them only 20 (2.4%) were detected and put on second line regimen. The incidence of immunological failure was 1.8 
cases per 100 person years of follow-up. Patients who had not disclosed their HIV status to any one had high risk of immunological failure 
compared with patients those who had disclosed their HIV status (AHR, 0.429; 95% CI 0.206 - 0.893; P-value=0.024). Conclusion: Non 
disclosures of HIV status and with ambulatory of baseline functional status were found to be predictors of immunological failure. Most of the 
immunological failure cases were not detected early and not switched to second line ARV regimen. So patients with the above risk factors should 
be considered for a timely switch to second line HAART. 
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The human immunodeficiency virus (HIV) epidemic continues to be 
a major challenge to global health. In 2011, an estimated 34 million 
people were living with human immunodeficiency virus /acquired 
immunodeficiency syndrome (HIV/AIDS) worldwide; of them 22.9 
million were living in Sub-Saharan Africa [1]. According to 2011 
Ethiopia Demographic Health survey (EDHS) and 2012 country 
report the estimated adult prevalence of HIV is 1.5% [2-4].In 
Ethiopia considering the magnitude of the problem use of Highly 
Active Antiretroviral therapy (HAART) started in 2003 as a fee based 
treatment and then launched free ART in 2005 and by the end of 
January 2009 an estimated 180,447 clients had been enrolled in 
ART [5]. According to HEALTH SECTOR DEVELOPMENT 
PROGRAMME (HSDP) national report the total number of HIV 
positive people was estimated at 1,216,908 and out of them, 
397,818 were eligible for ART, 333,434 ever started and 247,805 
currently on ART [6]. According to 2010 Ethiopian national report 
only 865 adults and 13pediatric patients are on second line regimen 
which accounts only 0.6%. Immunological failure is defined as: fall 
of CD4 count to pre-therapy base line, 50% fall from the on 
treatment peak value, or persistent CD4 levels below 100cells/mm3 
[4]. Knowing factors that can help to predict treatment failure will 
help to identify clients that are at higher risk of treatment failure so 
as to change regimen for those who already have failed regimen 
and delay though maximizing follow in those have potential failure. 
Routine patient follow-up need to be done as part of the routine 
clinical follow up and need to have a high index of suspension. 
Studies shows that only a few patients among those who actually 
had treatment failure were detected at the ART centers. The mean 
duration of treatment failure on first line ART and the mean 
duration from detection of treatment failure to switch to second line 
ART were longer [3]. Different studies from South Africa, Malawi, 
Ethiopia and Haiti revealed that the prevalence of treatment failure 
range from 9.8% -15% [6,3]. There are various risk factors 
described in different studies and world health Organization (WHO) 
guidelines [7].Yet published data on determining of magnitude and 
associated factors of Immunological failure are limited. Risk factors 
for Immunological failure have not been studied in this area. So the 
aim of this study was to assess the magnitude and associated 
factors of Immunological failure among adult and adolescent HIV 
infected Patients (with age ≥15yrs) on HAART and to provide 
information to optimize assessing of Immunological failure among 





Study area and period  
  
The study was conducted in St. Luke and Tulubolo Hospitals, south 
west Shoa zone, Oromia region St. Luke hospital is located in Woliso 
town and at distance of 125 Km and Tulubolo hospital is located in 
Tulubolo town which is 95 km away from Addis Ababa, the capital 
city of Ethiopia. St. Luke Hospital ever enrolled HIV positive 
clients/patients to chronic HIV care starting from April 2006-July 
2013 who's age ≥15 years is 3478 (F=2134, M=1344) and patients 
ever started on Highly Active Antiretroviral Therapy (HAART) for the 
same age and period is 2126 (F=1225, M=901). For Tulubolo 
Hospital number of patients ever enrolled in HIV chronic care 
starting from May 2010-July 2013 (the Hospital has started ART 
service in May 2010) who's age ≥15 years is 218 (F=142, M=76) 
and patients put on Highly Active Antiretroviral Therapy (HAART) for 
the same age is 130 (F=82, M=48) and the study period was from 
April 2006 up to July 2013.  
  
Study design  
  
Institutional based retrospective follow up study was carried out 
among HIV-positive patients on HAART for ≥12 months. Hence the 
chart of HIV positive patients on HAART for ≥12 months between 
April 2006 and July 2013 were reviewed retrospectively.  
  
Source population  
  
Source population was all human immune Deficiency Virus (HIV) 
infected patients with age ≥15yrs who were on first line 
Antiretroviral Therapy (ART) regimen in St. Luke and Tulu Bolo 
Hospitals. Study population  
  
The study population was all HIV infected patients with age ≥15yrs 
who started first line ART in St. Luke and Tulu Bolo Hospitals since 
April 2006-July 2013.  
  
Sample size determination Double proportional formula  
  
nj=Zα/2√(1+1/r)P(1-P)+Zβ√P1(1-P1)+P2(1-P2)/r (P1-P2)2  
  
was used to determine the sample size of the study; EPI-info 
version 3.5.3 window is used with type 1 error 5%, power of 80% 
and ratio of exposed to unexposed 1:1, and the sample size has 
been calculated for exposure status in different variables using the 
following formula. Proportion of exposure status in these variables is 
taken from previous studies [8, 9].And the final sample size for the 
study was 828.  
  
Sampling procedure:  
  
Two hospitals which are found in south west shoa zone were used. 
From both hospitals HIV patients on HAART for ≥12 months has 
been were selected. The calculated final sample size was 828 with 
zero none response rate. Systematic random sampling is employed 
after proportional allocation of the sample for both Hospitals.  
  
Study variables  
  
The dependent variable of the study was immunologic failure. The 
independent variables include Socio demographic characteristics, 
Behavioral status and Base line clinical and Laboratory information. 
 
 Data collection methods and instrument used  
  
To ensure consistency of the data electronic data base, registrations 
and patient charts was used to extract the data. The data were 
collected by preparing chart abstraction form.  
  
Data quality control  
  
Before data collection the data collectors and supervisors were get a 
one day orientation by principal investigator. The data collectors 
were Hospitals data clerks and the supervisors were Hospitals ART 
providers. There was a regular supervision to data collectors by the 
principal investigator and supervisors to maintain the data quality.  
  
Data analysis  
  
The data was entered to Epi-data 3.1 version and analyzed using 
SPSS version 20.Descriptive analysis using frequency and summary 
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statistics was conducted to describe the study subject. Immunologic 
failure distribution within groups in respect to time after initiation of 
therapy is estimated using Kaplan Meier method and log rank tests. 
Bivariate Cox regression analysis has been used to determine the 
association between independent variables and covariates with 
significant association (p value  
  
Ethical consideration  
  
The study was approved by an ethical committee in Addis 
Continental Institute of Public Health. A support letter to the two 
Hospitals was obtained from the institute before conducting the 
data collection. The information that was collected by the study 




Base line socio demographic and socio clinical character: 
from a total of 828 patients data reviewed retrospectively 57.6% 
(477) of them were female. 61.1% (506) were married and followed 
by 14.7% (122) widower, 10.4% (86) never married. The median 
age of the participant at enrollment was 32.00 year (IQR, 27-39yrs) 
and 45.7% (378) go through primary education (Table 1).  
  
Base line clinical and laboratory information: about 82.5% of 
patients were working in their functional status at a time of 
enrollment. The commonest documented OI at time of enrollment 
were herpes Zoster, followed by oral thrush and TB which accounts 
22.3%, 15.8% and 13.7% respectively. At base line the median CD4 
count was 148cells/mm3 (IQR, 100-200) and the mean Hemoglobin 
was 12.08g/dl (SD, 1.934). 99.5 %( 824) were given cotrimoxzole 
at the time of ART initiation. At base line 33.5 %( 278) of the 
participants were on WHO staging 3 and 4. Thirty nine point two 
percent (325) of participants know their spouse HIV status (Table 
2).  
  
Magnitude of Immunological failure: a total of 828 patients 
were followed retrospectively for a median time of 44 months (IQR 
32-56) with a minimum of 18 and maximum 97 months follow up 
from April 2006-July 2013. Out of 828 patients 6.8% (56) developed 
immunological failure. The incidence of immunological failure was 
1.8 cases per 100 person years of follow-up.  
  
Time of Immunological failure: the median time of failure for 
those qualified immunological failure was 48 months (IQR 35-65 
months). Life table showed treatment failure started by 24 month 
follow-up with 16% and similarly 13%, 6%, 26%, 14%, 12% for the 
month of 30, 36, 42, 48, and 54 respectively. A sharp drop is seen 
at 84th month. Life table distribution and the survival function curve 
is shown in Table 3 and Figure 1. The findings of survival 
functions between groups were compared using Kaplan-Meier 
method. To see the significant differences between the groups the 
Log rank test was used and the result is shown in Table 4, Table 
5.  
  
Predictors of Immunological failure: in bivariate Cox regression 
CD4 count and disclosure of HIV status were statistically significant. 
Significance difference was seen for two variables. When survival 
time for disclosure status was compared, those patients who didn't 
disclose their HIV status to family member had significantly lower 
mean survival time, 45.3 with P value=0.016.Significant difference 
was seen between CD4 count below or equal to 200cell/mm3 and 
greater than 200cell/mm3, time to failure in the latter group was 
shorter (P value=0.013).No significant association was observed 
between age, sex, educational status, employment status, marital 
status, and base line weight of the patient, presence of OI, baseline 
WHO stage, baseline functional status, presence of past TB and 
time to Immunological failure. The variable that were found to be 
significantly associated with immunological failure in bivariate and 
those with P-value ≤0.2 in Bivariate Cox regression were entered in 
to multivariate Cox-model. Age and sex was also entered in to the 
model irrespective of their association to immunological failure as 
they are the commonest confounders. The multivariate model 
analysis made evident that disclosure status was significantly 
associated with immunological failure at P-value less than 0.05 and 
from the Bivariate Cox regression, functional status was found to be 
significantly associated with immunological failure. Patients who 
didn't disclose their HIV status to any one had high risk of 
developing immunological failure compared with patients those who 
had disclose their HIV status (AHR, 0.429; 95% CI 0.206 - 0.893; P-
value=0.024). Patients with base line functional status ambulatory 
had risk of developing immunological failure than patients with 
working and bedridden functional status (HR, 0.337; 95% CI 0.137-





In this retrospective follow-up study Patients on follow-up 
contributed a total of 3116 person years and incidence of 
immunological failure was 1.8 per 100 person years of follow-up 
(PYFUS). From the study found that the independent significant 
predictors of Immunological failure in patients living with HIV/AIDS 
after initiation of ART were not disclosing of HIV status to any one 
of family member and being ambulatory in baseline functional 
status. As per the WHO and/national ART guide line definition 6.8% 
of patients had developed immunological failure. The finding is 
consistent with the finding from India where the prevalence of 
Immunological failure is 7.3% in participants who had been on 
HAART for a median of 17 months (IQR:6-30 months) and study 
conducted in Kenya which shows immunological failure 5.7% [10-
13].The median pre HAART CD4 count observed in this study is 
148cell/ mm3 which is also comparable with studies conducted in 
Djibuti with median CD4 count 144cell/mm3 and study conducted in 
Tanzania with median CD4 count 159 cells/mm3 (IQR; 65-234) [8, 
11, 14].In bivariate cox regression base line CD4 count ≥ 200/mm3 
was statistical association in Immunological failure, In contrast 
studies conducted in India and other sites showed that low Cd4 
count (13,8].  
  
Limitation of the study  
  
This study was conducted retrospectively on Patients chart review. 
So that most reviewed charts have got missed laboratory tests like 
platelet counts and pre HAART viral load determination was not 
included in the study due to absence of Viral load laboratory test in 





According to this study the majority of patients with immunological 
failure were not diagnosed timely and not switched to second line 
regimen. So knowing the predictor factors and timing of failure are 
important parts for care and treatment. Having ambulatory 
functional status at base line and disclosing of HIV status to family 
members has identified the independent significant predictors of 
immunological failure in patients living with HIV/AIDS after initiation 
of HAART by this study. Based on the finding, the following 
recommendations were forwarded. Baseline CD4 counts 
>200cell/mm3 should needs further study, sensitization of health 
care providers to focus on immunological failure and health care 
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Table 1: baseline socio demographic characteristics of HIV patients on 
HAART in St.Luke and Tulubolo Hospitals, April 2006-July 
2013.(n=828),Ethiopia 
Variable  Frequency Percent 
Age      
  15-24 81 9.8 
    25-34 377 45.5 
  35-44 253 30.6 
   >=45 117 14.1 
Sex      
  Male 351 42.4 
  Female 477 57.6 
Marital status     
   Never Married 86 10.4 
   Married 506 61.1 
   Divorced 44 5.3 
   Separated 70 8.5 
   Widowed 122 14.7 
Educational status     
   No Education 198 23.9 
    Primary 378 45.7 
   Secondary 214 25.8 
   Tertiary 38 4.6 
Patient referral     






   From outside the facility 140 16.9 
Employment status     
   Employed 279 33.7 
   Unemployed 549 66.3 
Religion     
   Orthodox 530 64.0 
   Muslim 105 12.7 
   Protestant 175 21.1 
   Catholic 12 1.4 
   ^Others 6 0.7 
Condition of spouse     
   Healthy 175 21.1 
   Chronically ill 





   Unknown 255 30.8 
^ Patients other than mentioned religions 
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Table 2:  base line clinical and laboratory information of HIV patients 
on HAART in St.Luke and Tulu Bolo Hospitals, Ethiopia,April 2006-July 
2013 (N=828) 
Variable frequency Percent 
Weight  
  
   <50 461 55.7 
   ≥50 367 44.3 
Functional status 
  
    
  Working 670 80.9 
   Ambulatory 133 16.1 
   Bedridden 25 3.0 
WHO stage 
  
   Stage 1 281 33.9 
   Stage 2 316 38.2 
   Stage 3 183 22.1 
   Stage 4 48 5.8 
Base line CD4 
  
   ≤200cell/mm3 619 74.8 
   >200cell/mm3 201 24.3 
Base line CPT 
  
   Yes 824 99.5 
   No 4 0.5 
Base line TB 
  
   Yes 109 13.2 
   No 719 86.8 
Base line Hgb 
  
   <9 g/dl 53 6.4 
   9-11 g/dl 207 25 































Table 3: Life table distribution of probability of immunological failure of patients on HAART  St.Luke and Tulu Bolo Hospital, 
























Surviving at End 
of Interval 
0 65 0 65.000 0 0.00 1.00 1.00 
6 65 0 65.000 0 0.00 1.00 1.00 
12 65 0 65.000 0 0.00 1.00 1.00 
18 65 0 65.000 0 0.00 1.00 1.00 
24 65 1 64.500 10 0.16 0.84 0.84 
30 54 0 54.000 7 0.13 0.87 0.74 
36 47 1 46.500 3 0.06 0.94 0.69 
42 43 2 42.000 11 0.26 0.74 0.51 
48 30 1 29.500 4 0.14 0.86 0.44 
54 25 0 25.000 3 0.12 0.88 0.39 
60 22 1 21.500 8 0.37 0.63 0.24 
66 13 2 12.000 1 0.08 0.92 0.22 
72 10 0 10.000 5 0.50 0.50 0.11 
78 5 0 5.000 3 0.60 0.40 0.04 
84 2 1 1.500 1 0.67 0.33 0.01 
Six month interval was taken from the WHO and National guide line which is recommended for immunological follow-up 
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Table 4:  Kaplan-Meier and log rank analysis for comparison of survival time for patients on HAART according 




95% Confidence Interval 
 
Lower Upper Log rank test 
Sex 
     
0.083    Male 54.8 48.1 61.6 
   Female 47.6 41.3 53.9 
Age 
   
  
0.56 
   15-24 44.4 33.9 54.8 
   25-34 52.9 44.6 61.2 
   35-44 51.8 44.3 59.3 
    >=45 51.7 40.5 62.9 
Education 
   
  
0.056 
   NoEducation 47.5 37.8 57.1 
   Primary 48.0 41.4 54.7 
   Secondary 56.8 47.9 65.6 
   Teritiary 77.6 67.5 87.8 
Marital status 





   Never Married 47.3 34.1 60.5 
   Married 52.4 46.3 58.4 
   Divorced 61.5 59.4 63.5 
   Separated 51.0 44.4 57.5 
   Widowed 47.3 32.2 62.3 
Patient referral 
   
  
0.48 
  From within the facility or hospital 50.6 45.5 55.7 
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Table 5:  Kaplan-Meier and Log rank analysis for comparison of survival time for patients on HAART according to base 
line information, April, 2006-July, 2013. (N=828) 
Variable Mean survival 95% Confidence Interval Log rank test 
Lower Upper 
Disclosure status       
  
0.016# 
   Yes 54.4 48.3 60.5 
   No 45.3 39.5 51.1 





    
0.23 <50 53.3 46.9 59.6 
>=50 49.0 42.1 55.9 











   Stage1 45.4 36.0 54.9 
   Stage2 54.2 48.1 60.4 
   Stage3 52.9 40.0 65.7 
   Stage4 64.5 54.7 74.2 
OI at base line       
  
0.17 
   Yes 53.9 48.8 59.0 
   No 45.6 34.6 56.7 
Base line CD4       
  
0.013# 
   <=200 54.9 48.9 60.9 
   >200 43.5 37.0 50.0 
Functional status       
  
0.2 
   Working 49.3 44.2 54.3 
   Ambulatory 61.7 50.9 72.4 
   Bedridden 50.5 8.3 92.6 






0.15   Yes 63.375 50.7 76.0 
   No 49.964 45.0 54.8 
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Table 6: cox proportional hazard analysis with bivariate and multivariate model for socio demographic, clinical and laboratory, 






Crude HR (95% CI) Adjusted HR#(95% CI) 
Sex         
  
0.737(0.323-1.683) 
   Male 30(8.5) 321(91.5) 1 
   Female 26(5.5) 451(94.5) 0. 627 (0.365-1.075 
Age         
   15-24 5(6.2) 76(93.8) 1   
   25-34 23(6.1) 354(93.9) 1.847 (0.610-5.591)   
    35-44 19(7.5) 234(92.5) 0.913 (0.6416-2.00)   
    >=45 9(7.7) 108(92.3) 0.978 (0.440-2.172)   
Education         
   No Education 12(6.1) 186(93.9) 1   
   Primary 30(7.9) 348(92.1) 1.023 (0.543-2.040)   
   Secondary 13(6.1) 201(93.9) 0.635 (0.284-1.418)   
   Teritiary 1(2.6) 37(97.4) 0.125 (0.016-0.967)   
Patient referral         
   From within 
the   hospital 50(7.3) 638(92.7) 1   
   From outside 
the facility 6(4.3) 134(95.7) 1.352 (0. 574 -3.180)   






Table 7: cox proportional hazard analysis with bivariate and multivariate model for socio demographic, clinical and laboratory, HIV patients 






Crude HR (95% CI) Adjusted HR# (95% CI) 
Disclosure status 
    
   Yes 38(6.8) 517(93.2) 2.056(1.120-3.774) 0.429(0.206-0.893)@ 
   No 18(6.6) 255(93.4) 1 1 
WHO stage 
    
   Stage 1 17(6.1) 264(93.9) 1 
 
   Stage 2 25(7.9) 291(92.1) 1.916 (0.637-5.761) 
 
   Stage3 10(5.5) 173(94.5) 1.182(0.408-3.426) 
 
   Stage4 4(8.3) 44(91.7) 1.124 (0. 342-3.688) 
 
Base line CD4 count 
(N=820) 
      
  
0.517(0.253-1.057)    <=200 38(6.1) 581(93.9) 0.469 (0.252-0.872) 
   >200 16(8) 185(92) 1 
Functional status 
    
   Working 43(6.4) 627(93.6) 1 1 
   Ambulatory 11(8.3) 102(91.7) 0. 557 (0.274-1.130) 0.337(0.137-0.828)@ 
   Bedridden 2(8) 23(92) 1.044 (0 .250-4.354) 0.599(0.111-3.216) 
Weight 
    
   <50 34(7.4) 427(92.6) 0.718 (0.412-1.253) 
 
   >=50 22(6) 345(94) 1 
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Figure 1: cumulative probability of not developing immunological failure for patients after initiation of HAART, 
St.Luke and Tulu Bolo Hospital, April 2006-July 2013 
 
 
 
 
